Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedCap ABSTU:61MA +2.23%80 Altman Z-Score is 5.33 as of Jul. 17, 2026, which is 7% above its 10-year median of 4.99. GuruFocus rates STU:61MA with a GF Score™ of 80/100 and a GF Value™ of €50.29. Among 808 Medical Devices & Instruments companies, MedCap AB ranks better than 66.83% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 5.32 is strong.
MedCap AB has a Altman Z-Score of 5.33, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for MedCap AB's Altman Z-Score or its related term are showing as below:
STU:61MA'
s Altman Z-Score Range Over the Past 10 Years
Min: 2.43 Med: 4.99 Max: 9.96
Current: 5.32
During the past 13 years, MedCap AB's highest Altman Z-Score was 9.96. The lowest was 2.43. And the median was 4.99.
MedCap AB (STU:61MA) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
MedCap AB Altman Z-Score Related Terms
MedCap AB Altman Z-Score Historical Data
* Premium members only.
The historical data trend for MedCap AB's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:61MA vs ABT, SYK, MDT: Altman Z-Score Comparison
For the Medical Devices subindustry, MedCap AB's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedCap AB Altman Z-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where MedCap AB's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
MedCap AB's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.2123
+
1.4
*
0
+
3.3
*
0.1232
+
0.6
*
6.4516
+
1.0
*
0.7945
=
5.33
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
MedCap AB (STU:61MA) has a Altman Z-Score of 5.33 as of Jul. 17, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on MedCap AB and its competitors. This is near median its historical median of 4.99. Over the past decade, MedCap AB's Altman Z-Score has ranged from 2.43 to 9.96. According to the industry distribution chart, MedCap AB ranks #268 out of 808 companies in the Medical Devices & Instruments industry, placing it in the top 33.2%.
Is MedCap AB's Altman Z-Score too high?
MedCap AB's current Altman Z-Score of 5.33 is near median its 10-year median of 4.99. Over the past 10 years, this metric has ranged from a low of 2.43 to a high of 9.96. The Medical Devices & Instruments industry median Altman Z-Score is 3.02. MedCap AB's value of 5.33 is 76.5% above this industry median. Based on the distribution chart, MedCap AB ranks #268 out of 808 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, MedCap AB has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's Altman Z-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MedCap AB ranks #268 out of 808 companies for Altman Z-Score. This puts MedCap AB in the upper half of its industry. The industry median Altman Z-Score is 3.02. MedCap AB's value of 5.33 is 76.5% above this benchmark. Historically, MedCap AB's own Altman Z-Score has ranged from 2.43 to 9.96 over the past decade. While the company's 10-year median is 4.99 vs. the industry median of 3.02, MedCap AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Devices & Instruments company?
The median Altman Z-Score among Medical Devices & Instruments companies is 3.02, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedCap AB's current Altman Z-Score of 5.33 is 76.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on MedCap AB and its competitors. For the Medical Devices & Instruments industry, the median Altman Z-Score is 3.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedCap AB's current Altman Z-Score is 5.33, which is near median its own 10-year median of 4.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
MedCap AB (STU:61MA) has a current Altman Z-Score of 5.33. The stock's GF Value™ is €50.29, compared to a current price of €46.70 — trading 7.1% below its estimated fair value. The current Altman Z-Score is 5.33, which is near median its 10-year median of 4.99 and 76.5% above the Medical Devices & Instruments industry median of 3.02. MedCap AB's overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For MedCap AB (STU:61MA), the current Altman Z-Score is 5.33 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedCap AB (STU:61MA) Overvalued in 2026?
Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued.
The current stock price of €46.70 is trading 7.1% below its estimated GF Value™ of €50.29.
Key valuation signals for STU:61MA:
Altman Z-Score: 5.33 (near median its 10-year median of 4.99)
GF Value™: €50.29 vs. price of €46.70 (7.1% below fair value)
Industry Position: 76.5% above the Medical Devices & Instruments median (#268 of 808)
No single metric tells the full story. See the STU:61MA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
80GF Score
Get the complete analysis for STU:61MA
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:61MA has been successfully added to your 
